

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACTAVIS LABORATORIES FL, INC., AMNEAL
PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF NEW
YORK, LLC, DR. REDDY'S LABORATORIES, INC., DR. REDDY'S
LABORATORIES, LTD., SUN PHARMACEUTICALS INDUSTRIES,
LTD., SUN PHARMACEUTICALS INDUSTRIES, INC., TEVA
PHARMACEUTICALS USA, INC., WEST-WARD PHARMACEUTICAL
CORP., and HIKMA PHARMACEUTICALS, LLC
Petitioners

v.

JANSSEN ONCOLOGY, INC
Patent Owner

Case IPR2017-00853
Patent 8,822,438

Mailed: March 8, 2017

Before GREEN T.D., *Trial Paralegal*

NOTICE OF FILING DATE ACCORDED TO PETITION
AND
TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

The petition for *inter partes* review in the above proceeding has been accorded the filing date of February 8, 2017.

A review of the petition identified the following defect(s):

The file uploaded as “Exhibit 1029” does not conform with the requirements for papers 37 C.F.R. § 42.63(d)(1)(i). Specifically, Ex. 1029 is labeled as Ex. 1028.

Petitioner must correct the defect(s) within **FIVE BUSINESS DAYS** from this notice. Failure to correct the defect(s) may result in an order to show cause as to why the Board should institute the trial. No substantive changes (e.g., new grounds) may be made to the petition.

Patent Owner may file a preliminary response to the petition no later than three months from the date of this notice. The preliminary response is limited to setting forth the reasons why the requested review should not be instituted. Patent Owner may also file an election to waive the preliminary response to expedite the proceeding. For more information, please consult

Case
Patent No.

the Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 (Aug. 14, 2012), which is available on the Board Web site at <http://www.uspto.gov/PTAB>.

Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.

The parties are encouraged to use the heading on the first page of this Notice for all future filings in the proceeding.

The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel *pro hac vice* requires a showing of good cause. The parties are authorized to file motions for *pro hac vice* admission under 37 C.F.R. § 42.10(c). Such motions shall be filed in accordance with the “Order -- Authorizing Motion for *Pro Hac Vice* Admission” in Case IPR2013-00639, Paper 7, a copy of which is available on the Board Web site under “Representative Orders, Decisions, and Notices.”

The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in Patent Trial and Appeal Board End to End (PTAB E2E), accessible from the Board Web site at <http://www.uspto.gov/PTAB>. To file documents, users must register with PTAB E2E. Information regarding how to register with and use PTAB E2E is available at the Board Web site.

If there are any questions pertaining to this notice, please contact T.D. Green at 571-272-0327 or the Patent Trial and Appeal Board at 571-272-7822.

Case
Patent No.

PETITIONER:

Actavis Laboratories FL Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054

Hikma Pharmaceuticals LLC
Bayader Wadi Sheer
P.O. Box 182400
Amman, 1118, JO

PATENT OWNER:

Janssen Oncology, Inc.
10990 Wilshire Blvd
Suite 1200
Los Angeles, CA 90024

Case
Patent No.

Johnson & Johnson
Attn: Joseph F. Shirtz
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003